Poster Abstract Session:
145. PK/PD Studies
Friday, October 5, 2018: 12:30 PM-1:45 PM
Room: S Poster Hall

Tracks: Adult ID, Epidemiology and Infection Control, Investigative ID, Pediatric ID

Determination of the Arbekacin Exposure Required to Prevent Amplification of Resistant Subpopulations Using Patient Pharmacokinetics Simulated in a Hollow-Fiber Infection Model (HFIM)
Brian D. VanScoy, B.S.; Elizabeth A. Lakota, Pharm.D., M.S.; Sujata M. Bhavnani, Pharm.D., M.S.; Greg Giesel, B.S.; Ana I. Carranco, B.S.; Yu Nagira, M.S.; Shohei Ouchi, M.S.; Kenichiro Kondo, Ph.D.; Paul G. Ambrose, Pharm.D., FIDSA
Effect of Absolute Body Weight on Clinical Outcomes of Obese Patients Treated with Cefepime
Jamie L. Wagner, PharmD; Austin R. Morrison, PharmD Candidate; J. Taylor Loper, PharmD Candidate; Katie E. Barber, PharmD; Kayla R. Stover, PharmD, BCPS
Impact of Total Body Weight on Efficacy of Ceftriaxone in Obese Patients
Jamie L. Wagner, PharmD; J. Taylor Loper, PharmD Candidate; Austin R. Morrison, PharmD Candidate; Kayla R. Stover, PharmD, BCPS; Katie E. Barber, PharmD
  • ID Week_CTX_FINAL.pdf (395.0 kB)
  • Acute kidney Injury with Piperacillin-Tazobactam and Vancomycin in the Intensive Care Unit
    Tameka Smith, MS; James Lewis, PharmD, FIDSA; Graeme N. Forrest, MBBS, FIDSA
    RSV Monoclonal Antibody (MK-1654) Phase 1 Pharmacokinetics (PK) in Healthy Adults and Population PK Modeling to Support Pediatric Development
    Brian Maas, PharmD; Antonios Aliprantis, MD, PhD; Dennis Wolford, MS; Ghassan Fayad, PhD; Kalpit Vora, PhD; Dong Geng, PhD; Hua Ma, PhD; Luzelena Caro, PhD
    Efficacy of Ceftazidime-Avibactam in Combination with Aztreonam (COMBINE): Solutions for Metallo-β-lactamase producing-Enterobacteriaceae (MBL)
    Thomas P. Lodise, PharmD, PhD; Nicholas M. Smith, Pharm.D.; Patricia Holden, B.S.; J Nicholas O'Donnell, PharmD, MSc; Tyler Bedard, Pharm.D.; Robert A. Bonomo, MD; Brian T. Tsuji, PharmD
    Efficacy of Repeat Dosing of Oral Fosfomycin in a Dynamic Bladder Infection In Vitro Model
    Iain Abbott, MBBS FRACP FRCPA; Rixt Wijma, PharmD; Nick Broos, .; Anton Peleg, MBBS PhD MPH; Johan Mouton, MD PhD
  • IDWEEK2018 poster FINAL.pdf (7.0 MB)
  • Phase I study to evaluate the safety and pharmacokinetics (PK) of single and multiple ascending doses (SAD/MAD) of intravenous (IV) minocycline in healthy adult subjects
    Oliver A. Cornely, MD; Dorothee Arenz, MSc; Olivier Barraud, MD; Mark Bayliss, PhD; Vassiliki Dimitriou, Dipl.-Pharm.; Stefanie Hamacher, MSc; Andrew M. Lovering, PhD; Alasdair MacGowan, MD; Sue K. Cammarata, MD; Karen Fusaro, BA; David C. Griffith, BA; Elizabeth Morgan, BS; Jeffery S. Loutit, MBChB
    Dose Discrimination for ASN100: Bridging from Rabbit Survival Data to Predicted Activity in Humans Using a Minimal Physiologically-Based Pharmacokinetic (mPBPK) Model
    Christopher M. Rubino, Pharm.D.; Lukas Stulik, MSc; Harald Rouha, PhD; Zehra Visram, PhD; Adriana Badarau, PhD; Scott A. Van Wart, Ph.D., M.S.; Paul G. Ambrose, Pharm.D., FIDSA; Matthew M. Goodwin, Pharm.D., MBA; Eszter Nagy, MD, PhD
    Pharmacokinetic/Pharmacodynamic (PK/PD) Evaluation of a Novel Aminomethylcycline Antibiotic, KBP-7072, in the Neutropenic Murine Pneumonia Model Against S. aureus (SA) and S. pneumoniae (SPN)
    Alexander J. Lepak, M.D.; Miao Zhao, MS, PhD; Qingmei Liu, MS; Ping Wang, MS; Yanli Wang, MS; Justin C. Bader, Pharm.D., MBA; Paul G. Ambrose, Pharm.D., FIDSA; David R. Andes, M.D., FIDSA
  • kbp poster final.pdf (186.3 kB)
  • Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Rezafungin (RZF) Dose Selection in Treatment of Candida
    Elizabeth A. Lakota, Pharm.D., M.S.; Harish Ganesan, M.S.; Shawn Flanagan, PhD; Voon Ong, Ph.D.; Taylor Sandison, MD, MPH; Sujata M. Bhavnani, Pharm.D., M.S.; Christopher M. Rubino, Pharm.D.; Paul G. Ambrose, Pharm.D., FIDSA
    Vancomycin Area under the Curve (AUC) to Predict Nephrotoxicity: A systematic Review and Meta-analysis of observational studies
    Doaa Aljefri, PharmD, MSc; Sean Avedissian, PharmD; Nathaniel J. Rhodes, PharmD, MSc, BCPS; Michael Postelnick, RPh BCPS AQ ID; Marc H. Scheetz, PharmD, MSc, BCPS AQ-ID
    Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Inhaled ME1100 Dose Selection
    Sujata M. Bhavnani, Pharm.D., M.S.; Jeffrey P. Hammel, M.S., B.S.; Elizabeth A. Lakota, Pharm.D., M.S.; Brian D. VanScoy, B.S.; Yu Nagira, M.S.; Christopher M. Rubino, Pharm.D.; Nobuo Sato, Ph.D.; Tomokazu Koresawa, M.S.; Kenichiro Kondo, Ph.D.; Paul G. Ambrose, Pharm.D., FIDSA
    A Translational Pharmacokinetic Rat Model of Cerebral Spinal Fluid (CSF) and Plasma Concentrations of Cefepime
    Jiajun Liu, PharmD; Sean Avedissian, Pharm.D.; Gwendolyn Pais, PhD; Medha Joshi, PhD; Nathaniel J. Rhodes, PharmD, MSc, BCPS; Marc H. Scheetz, PharmD, MSc, BCPS AQ-ID
  • CefeCSF_IDWeek_FINAL.pdf (857.5 kB)
  • Predictions of Isavuconazonium Sulfate Dosage in Patients Aged 6 months - <18 years by Physiologically Based Pharmacokinetic Modeling
    Amit Desai, PhD; Laura Kovanda, PhD; Christopher Lademacher, MD; William Hope, BMBS, FRACP, FRCPA, PhD; Michael Neely, MD, MSc, FCP; Peter Bonate, PhD; Andrea Edginton, PhD
    Efficacy of Daptomycin Combination with ß-lactams for Daptomycin Resistant Enterococcus faecium Harboring LiaSR Substitutions
    Razieh Kebriaei, Ph.D.; Seth Rice, BSc; Kavindra Singh, Ph.D.; Kyle Stamper, BSc; An Dinh, BS; Rafael Rios, MSc; Lorena Diaz, PhD; Barbara Murray, M.D.; Jose M. Munita, MD; Truc T. Tran, PharmD; Cesar Arias, MD, PhD, FIDSA; Michael J. Rybak, PharmD, MPH, PhD
  • RO1-1-10-18-17.5.pdf (6.6 MB)
  • Mass Balance, Metabolism, and Excretion of [14C]-Plazomicin in Healthy Human Subjects
    Taylor Choi, PhD; Julie D. Seroogy, BS; Mitesh Sanghvi, PhD; Shyeilla V. Dhuria, PhD
  • 1400_ IDW Choi Poster_F.pdf (220.8 kB)
  • Daptomycin Combined with Low Dose Ceftriaxone Prevents the Emergence of Daptomycin Resistance against Streptococcus mitis-oralis Group in an In vitro Model of Simulated Endocardial Vegetations (SEVs)
    Razieh Kebriaei, Ph.D.; Seth Rice, BSc; Kyle Stamper, BSc; Cristina Garcia-De-La-Maria, PhD; Nagendra Mishra, PhD; Jose M Miro, MD, PhD; Cesar Arias, MD, PhD, FIDSA; Truc Tran, PharmD; Paul Sullam, MD; Arnold Bayer, MD, FIDSA; Michael J. Rybak, PharmD, MPH, PhD
    A Pharmacokinetic study on CMS and Colistin and its impact on clinical cure and acute kidney injury in critically ill patients with normal renal function from south India
    Vidya Menon, MD, FACP; Sangita Sudhir, PharmD; Merlin Moni, MD; Dipu Ts, MD; Zubair Mohammed, MD; Sabarish Balachandran, MD; Sanjeev Singh, DCH, MD, PhD; Payal Patel, MD, MPH; Keith S. Kaye, MD, MPH
    Augmented Renal Clearance Using Aminoglycoside Population-Based Pharmacokinetic Modeling With Bayesian Estimation in Children in the Pediatric Intensive Care Unit
    Sean Avedissian, Pharm.D.; Nathaniel Rhodes, PharmD, MSc; Yuna Kim, BS; Josh Valdez, BS; John Bradley, MD, FAAP; Jeniffer Le, Pharm.D., MAS, FCCP, FCSHP, BCPS-ID
    Disproportionality Analysis of Safety with Nafcillin and Oxacillin with the FDA Adverse Event Reporting System (FAERS)
    Tristan T. Timbrook, PharmD, MBA, BCPS; Jesse Sutton, PharmD; Emily Spivak, MD, MHS
  • Timbrook IDWeek 2018.pdf (317.5 kB)
  • Population Pharmacokinetic (PK) Model to Describe Epithelial Lining Fluid (ELF) Penetration of ASN-1 and ASN-2 after ASN100 Administration to Healthy Subjects
    Scott A. Van Wart, Ph.D., M.S.; Christopher Stevens, M.D.; Zoltan Magyarics, M.D., Ph.D.; Steven A. Luperchio, Ph.D., CMPP; Christopher M. Rubino, Pharm.D.; Paul G. Ambrose, Pharm.D., FIDSA
    Evaluation of Alternative Piperacillin-Tazobactam Dosing Strategies against ESBL-producing Enterobacteriaceae using a Hollowfiber Infection Model
    Henrietta Abodakpi, Pharm.D; Kai-Tai Chang, Ph.D; Ana Maria Sánchez-Díaz, Ph.D; Rafael Cantón, Pharm.D, Ph.D; Vincent Tam, Pharm.D
    Caspofungin and Anidulafungin Behave as Fungistatic Agents Against Candida auris.
    Catiana Dudiuk, PhD; Indira Berrio, MD, MSc; Laura Theill, PhD; Soraya Morales-Lopez, PhD; Soraya Salcedo, MD, MSc; Jose Rodriguez, MD; Soledad Gamarra, PhD; Guillermo Garcia-Effron, PhD
    A Phase IIa Efficacy, Safety, Tolerability and Pharmacokinetic (PK) Study of Encochleated Amphotericin B in Patients with Mucocutaneous (Esophogeal, Oropharyngeal, Vulvovaginal) Candidiasis Who are Refractory or Intolerant to Standard Non-Intravenous Therapies
    Lilian Kibathi, PharmD; Parag Kumar, PharmD; Michail Lionakis, M.D., Sc.D.; Amanda Urban, CRNP; Elise Ferre, PA-C, MPH; Maryellen McManus, RN, MPH; Benjamin Colton, PharmD; Chris Lambros, PhD; Ruying Lu, BS; Raphael Mannino, PhD; Edmund Tramont, MD, FIDSA; Alexandra F. Freeman, MD
    Inoculum Effect of Piperacillin/Tazobactam Concentration on Emergence of Resistance in Klebsiella aerogenes
    Marco Custodio, PharmD; Beverly Anderson, BA; Daniel Sanchez, BS; Keenan Ryan, PharmD, PhC; Carla Walraven, PharmD, MS; Renee-Claude Mercier, PharmD
    Implementation and Validation of a Vancomycin AUC/MIC Calculator and Dosing Protocol at a Large Community Hospital.
    Megan Seddon, PharmD; Kevin Scorgie, PharmD, BCPS; Sara Kutner, PharmD; Andre McMahon, PharmD; Jamie Kisgen, PharmD, BCPS (AQ-ID)
    Piperacillin/Tazobactam Therapeutic Drug Monitoring: True Interpatient Variability or Compound Instability?
    Ryan L. Crass, PharmD; Praveen Kumar, PhD; Twisha S. Patel, PharmD, BCPS; Manjunath P. Pai, PharmD
  • IDWeekPoster_RCRASS.pdf (318.6 kB)
  • Evaluating the Dissonance between Cmax and AUC with Clinically Utilized Aminoglycoside (AG) Dosing Regimens: Use of Tobramycin (TOB) Against Pseudomonas aeruginosa (PA) as a Case Study
    Nikolas J. Onufrak, Pharm.D.; Sujata M. Bhavnani, Pharm.D., M.S.; Jason M. Pogue, Pharm.D., BCPS-AQ ID; Christopher M. Rubino, Pharm.D.
    Pharmacokinetics (PK) and toxicity of intravenous amikacin (AMK) dosed three times a week (TIW) for treatment of disseminated Mycobacterium abscessus infection in children
    M. Tuan Tran, PharmD; Felice C Adler-Shohet, MD; Jasjit Singh, MD; Delma Nieves, MD; Negar Ashouri, MD; Antonio Arrieta, MD, FIDSA
    24-Hour Pharmacokinetic Relationships for Intravenous Vancomycin and Novel Urinary Biomarkers of Acute Kidney Injury
    Sean Avedissian, Pharm.D.; Jiajun Liu, PharmD; J Nicholas O'Donnell, PharmD, MSc; Gwendolyn Pais, PhD; Leighton Becher, BS; Medha Joshi, PhD; Walter Prozialeck, PhD; Peter Lamar, BS; Thomas P. Lodise Jr., PharmD, PhD; Marc H. Scheetz, PharmD, MSc, BCPS AQ-ID
    IV Brincidofovir (BCV): Pharmacokinetics (PK) and Safety of Multiple Ascending Doses (MAD) in Healthy Subjects
    Odin Naderer, PharmD; Virna Schuck, Ph.D.; Marion Morrison, MD; Maggie Anderson, BS; Thangam Arumugham, PhD; John Dunn, PhD
    Plasma and Intrapulmonary Pharmacokinetics of Sitafloxacin in Thai Critically Ill Patients with Pneumonia.
    Taniya Paiboonvong, MS; Preecha Montakantikul, Assoc. Prof.; Viratch Tangsujaritvijit, MD; Jaipak Kaemapairoj, MD
  • IDweek 2018_Sitafloxacin PK.pdf (460.0 kB)
  • Examining the relationship between vancomycin area under the concentration time curve and serum trough levels in adults with presumed or documented staphylococcal infections
    Laura Clark, PharmD; Lee P. Skrupky, PharmD; Ryan Servais, PharmD; Charles F. Brummitt, MD; Thomas J. Dilworth, PharmD
  • IDWeek 2018 Vanco AUC_FINAL.pdf (343.3 kB)
  • Population pharmacokinetic analysis of ciprofloxacin and levofloxacin in critically ill trauma, surgical, and burn patients
    Kelly Ivins-O'Keefe, BA (MD anticipated May 2018); Kevin S. Akers, MD, FIDSA; Taylor Schlotman, PhD

    CME Credits: Maximum of 0.00 hours of AMA PRA Category 1 Credit™

    Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 3rd with the exception of research findings presented at the IDWeek press conferences.